Van Kuilenburg A.B., Meinsma R., Zoetekouw L., Van Gennip A.H.

Pharmacogenetics 12:555-558(2002) GAD 139369 GeneRIF 1806 · Mapped (2)
Associated with PHARMACOGENOMIC: 5-fluorouracil- related toxicity; GAD 139369 High prevalence of the IVS14 + 1G>A mutation is found in the gene of patients with severe 5-FU-associated toxicity; Observational study of gene-environment interaction. (HuGE Navigator) GeneRIF 1806

Yamaguchi K., Arai Y., Kanda Y., Akagi K.

Jpn. J. Cancer Res. 92:337-342(2001) GeneRIF 1806 · Mapped (2)
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) GeneRIF 1806

Raida M., Schwabe W., Hausler P., Van Kuilenburg A.B., Van Gennip A.H., Behnke D., Hoffken K.

Clin. Cancer Res. 7:2832-2839(2001) GeneRIF 1806 · Mapped (2)
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) GeneRIF 1806

Raida M., Kliche K.O., Schwabe W., Hausler P., Clement J.H., Behnke D., Hoffken K.

J. Cancer Res. Clin. Oncol. 128:96-102(2002) GeneRIF 1806 · Mapped (2)
circadian expression seen in leukocytes of healthy subjects but rhythm disturbed in patients with advanced gastrointestinal carcinomas GeneRIF 1806

Johnson M.R., Wang K., Diasio R.B.

Clin. Cancer Res. 8:768-774(2002) GeneRIF 1806 · Mapped (2)
DPD deficiency resulting from a compound heterozygote is seen in proband of breast cancer patients GeneRIF 1806

van Kuilenburg A.B., Dobritzsch D., Meinsma R., Haasjes J., Waterham H.R., Nowaczyk M.J., Maropoulos G.D., Hein G., Kalhoff H., Kirk J.M. et al.

Biochem. J. 364:157-163(2002) GeneRIF 1806 · Mapped (2)
Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure GeneRIF 1806

Fujiwaki R., Hata K., Nakayama K., Moriyama M., Iwanari O., Katabuchi H., Okamura H., Sakai E., Miyazaki K.

Int. J. Cancer 99:328-335(2002) GeneRIF 1806 · Mapped (16)
TK1 gene expression together with TS TP and DPD gene expression may play important roles in influencing the malignant behavior of epithelial ovarian cancer. GeneRIF 1806

Celik I., Kars A., Guc D., Tekuzman G., Ruacan S.

Cancer Invest. 20:333-339(2002) GeneRIF 1806 · Mapped (2)
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) GeneRIF 1806

Hamdy S.I., Hiratsuka M., Narahara K., El-Enany M., Moursi N., Ahmed M.S., Mizugaki M.

Br J Clin Pharmacol 53:596-603(2002) GeneRIF 1806 · Mapped (22)
Observational study of genotype prevalence. (HuGE Navigator) GeneRIF 1806

Van Kuilenburg A.B., Meinsma R., Zoetekouw L., Van Gennip A.H.

Int. J. Cancer 101:253-258(2002) GeneRIF 1806 · Mapped (2)
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) GeneRIF 1806

Ichikawa W., Uetake H., Shirota Y., Yamada H., Nishi N., Nihei Z., Sugihara K., Hirayama R.

Clin. Cancer Res. 9:786-791(2003) GeneRIF 1806 · Mapped (8)
Gene expression is a predictor for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. GeneRIF 1806

Gross E., Seck K., Kiechle M.

Zentralbl Gynakol 124:574-579(2002) GeneRIF 1806 · Mapped (2)
Observational study of genetic testing. (HuGE Navigator) GeneRIF 1806

Schneider H.B., Becker H.

Eur. J. Med. Res. 8:226-228(2003) GeneRIF 1806 · Mapped (2)
A deficiency or mutation in this gene in patients with epithelial neoplasms might be the cause of toxicity when administered 5-FU. GeneRIF 1806

Omura K.

Int. J. Clin. Oncol. 8:132-138(2003) GeneRIF 1806 · Mapped (2)
The DPYD mutation associated with lack of DPD activity warrants genetic screening of these mutation before administration 5-FU for cancer patients. GeneRIF 1806

Kornmann M., Schwabe W., Sander S., Kron M., Strater J., Polat S., Kettner E., Weiser H.F., Baumann W., Schramm H. et al.

Clin. Cancer Res. 9:4116-4124(2003) GeneRIF 1806 · Mapped (8)
TS and DPD quantitation may be helpful to evaluate prognosis of patients receiving adjuvant 5-FU and that patients with high TS and low DPD may benefit from adjuvant 5-FU chemotherapy in colorectal cancer. GeneRIF 1806

Ichikawa W., Uetake H., Shirota Y., Yamada H., Takahashi T., Nihei Z., Sugihara K., Sasaki Y., Hirayama R.

Br. J. Cancer 89:1486-1492(2003) GeneRIF 1806 · Mapped (11)
high orotate phosphoribosyltransferase/dihydropyrimidine dehydrogenase ratio associated with longer survival in colorectal cancer patients treated with fluoropyrimidine-based chemotherapy GeneRIF 1806

Horiguchi J., Yoshida T., Koibuchi Y., Iijima K., Ninomiya J., Takei H., Yokoe T., Iino Y., Morishita Y.

Oncol. Rep. 11:65-72(2004) GeneRIF 1806 · Mapped (2)
DPD expression may function as a marker of DPD activity and may be a prognostic indicator for patients with breast cancer. GeneRIF 1806

Li H., Suo Z., Zhang Y., Risberg B., Karlsson M.G., Villman K., Nesland J.M.

Histol. Histopathol. 19:129-136(2004) GeneRIF 1806 · Mapped (13)
There is no prognostic significance to DHP mRNA expression in breast neoplasms. GeneRIF 1806

Salgueiro N., Veiga I., Fragoso M., Sousa O., Costa N., Pellon M.L., Sanches E., dos Santos J.G., Teixeira M.R., Castedo S.

Genet. Med. 6:102-107(2004) GeneRIF 1806 GAD 139372 · Mapped (2)
Associated with PHARMACOGENOMIC: 5-flurouracil toxicity; GAD 139372 Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) GeneRIF 1806

Zhu A.X., Puchalski T.A., Stanton V.P. Jr., Ryan D.P., Clark J.W., Nesbitt S., Charlat O., Kelly P., Kreconus E., Chabner B.A. et al.

Clin Colorectal Cancer 3:225-234(2004) GeneRIF 1806 · Mapped (2)
Observational study of gene-environment interaction. (HuGE Navigator) GeneRIF 1806

Hotta T., Taniguchi K., Kobayashi Y., Johata K., Sahara M., Naka T., Watanabe T., Ochiai M., Tanimura H., Tsubota Y.T.

Oncol. Rep. 11:1045-1051(2004) GeneRIF 1806 · Mapped (7)
In stages I and II DPD levels in the tumor specimens tended to be higher in the gastric cancer group than in the colorectal cancer group GeneRIF 1806

Mattison L.K., Ezzeldin H., Carpenter M., Modak A., Johnson M.R., Diasio R.B.

Clin. Cancer Res. 10:2652-2658(2004) GeneRIF 1806 · Mapped (2)
Observational study of genetic testing. (HuGE Navigator) GeneRIF 1806

Hsiao H.H., Yang M.Y., Chang J.G., Liu Y.C., Liu T.C., Chang C.S., Chen T.P., Lin S.F.

Cancer Chemother. Pharmacol. 53:445-451(2004) GeneRIF 1806 GAD 139362 GAD 139374 GAD 139371 · Mapped (2)
Not Associated with NORMALVARIATION: dihydropyrimidine dehydrogenase level; GAD 139371 Not Associated with PHARMACOGENOMIC: dihydropyrimidine dehydrogenase level; GAD 139362 GAD 139374 Observational study of genotype prevalence and gene-disease association. (HuGE Navigator) GeneRIF 1806

Hotta T., Kobayashi Y., Taniguchi K., Johata K., Sahara M., Watanabe T., Ochiai M., Tanimura H., Tsubota Y.T.

Oncol. Rep. 12:347-351(2004) GeneRIF 1806 · Mapped (7)
Thymidine phosphorylase and dihydropyrimidine dehydrogenase have roles in progression of liver metastasis GeneRIF 1806

Ichikawa W., Takahashi T., Suto K., Nihei Z., Shirota Y., Shimizu M., Sasaki Y., Hirayama R.

Int. J. Cancer 112:967-973(2004) GeneRIF 1806 · Mapped (8)
DPD in differentiated type malignant tissue was statistically lower than in normal stromal tissue (p < 0.001) but no difference was seen in undifferentiated type cases. GeneRIF 1806